Harrow updates 2025 revenue guidance to $270M-$280M as VEVYE and IHEEZO drive growth with major coverage win ahead
Source: SeekingAlpha
2025-11-11 14:12:31 ET
More on Harrow Health
- Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript
- Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential
- Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other
- Harrow Health Q3 2025 Earnings Preview
- Harrow to buy Melt Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Harrow updates 2025 revenue guidance to $270M–$280M as VEVYE and IHEEZO drive growth with major coverage win ahead
Harrow Health Inc.
NASDAQ: HROW
HROW Trading
-4.58% G/L:
$33.77 Last:
418,081 Volume:
$35.80 Open:
